We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodie... Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.12 | -6.74157303371 | 1.78 | 1.86 | 1.64 | 363794 | 1.73149839 | CS |
4 | -0.23 | -12.1693121693 | 1.89 | 2.15 | 1.64 | 353859 | 1.87859589 | CS |
12 | -0.04 | -2.35294117647 | 1.7 | 2.355 | 1.64 | 476114 | 1.96311148 | CS |
26 | -0.36 | -17.8217821782 | 2.02 | 3.62 | 1.36 | 651601 | 2.14063124 | CS |
52 | -0.94 | -36.1538461538 | 2.6 | 3.62 | 1.3 | 449380 | 2.22379366 | CS |
156 | -26.44 | -94.0925266904 | 28.1 | 46.4 | 1.3 | 648937 | 18.38727316 | CS |
260 | -25.94 | -93.9855072464 | 27.6 | 53.762 | 1.3 | 610529 | 22.32513553 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions